Table 2.
Comparative efficacy of different therapies for inducing and maintaining clinical remission in patients with moderate to severely active Crohn’s disease, based on network meta-analysis by Singh et al
| First-line therapy in biologic-naïve patients |
In patients with clinical response to induction therapy |
|||
|---|---|---|---|---|
| Induction of clinical remission (odds ratio vs. placebo) |
Probability of remissiona; SUCRA ranking |
Maintenance of clinical remission (odds ratio vs. placebo) |
Probability of remissionb; SUCRA ranking |
|
| Infliximab | 5.90 (2.78–12.51) | 60%; 0.93 | 2.86 (1.71–4.80) | 48%; 0.68 |
| Adalimumab | 3.80 (1.76–8.18) | 49%; 0.75 | 4.42 (2.68–7.29) | 58%; 0.97 |
| Certolizumab pegol | 1.36 (0.89–2.08) | 25%; 0.20 | 2.25 (1.51–3.35) | 42%; 0.48 |
| Vedolizumab | 2.69 (1.36–5.32) | 40%; 0.55 | 2.32 (1.40–3.84) | 42%; 0.52 |
| Ustekinumab | 2.75 (1.76–4.32) | 41%; 0.56 | 2.02 (1.35–3.03) | 39%; 0.36 |
a
Pooled placebo rate of inducing clinical remission in biologic-naïve patients=25%;
b
Pooled placebo rate of maintaining clinical remission in patients with response to induction therapy=24%
[Abbreviations: SUCRA=surface under the cumulative ranking curve]